OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
Julia Lai‐Kwon, Andrisha–Jade Inderjeeth, Karolina Lisy, et al.
European Journal of Cancer (2023) Vol. 184, pp. 83-105
Closed Access | Times Cited: 12
Julia Lai‐Kwon, Andrisha–Jade Inderjeeth, Karolina Lisy, et al.
European Journal of Cancer (2023) Vol. 184, pp. 83-105
Closed Access | Times Cited: 12
Showing 12 citing articles:
Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies
Meng‐Di Zhang, Haiying Qiu, Zheyi Han, et al.
International Journal of Pharmaceutics X (2025) Vol. 9, pp. 100316-100316
Closed Access | Times Cited: 1
Meng‐Di Zhang, Haiying Qiu, Zheyi Han, et al.
International Journal of Pharmaceutics X (2025) Vol. 9, pp. 100316-100316
Closed Access | Times Cited: 1
Cutaneous melanoma
Alpaslan Tasdogan, Ryan J. Sullivan, Alexander Katalinic, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Alpaslan Tasdogan, Ryan J. Sullivan, Alexander Katalinic, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
Jonathan N. Priantti, Maysa Vilbert, Thiago Madeira, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3754-3754
Open Access | Times Cited: 14
Jonathan N. Priantti, Maysa Vilbert, Thiago Madeira, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3754-3754
Open Access | Times Cited: 14
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113601-113601
Closed Access | Times Cited: 6
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113601-113601
Closed Access | Times Cited: 6
Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma
Nasreen Abdul Aziz, David Burke, Sharanniyan Ragavan, et al.
JCO Oncology Practice (2025)
Closed Access
Nasreen Abdul Aziz, David Burke, Sharanniyan Ragavan, et al.
JCO Oncology Practice (2025)
Closed Access
Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module
Mees Egeler, M van Leeuwen, Julia Lai‐Kwon, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114176-114176
Closed Access | Times Cited: 2
Mees Egeler, M van Leeuwen, Julia Lai‐Kwon, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114176-114176
Closed Access | Times Cited: 2
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL
Anne Rogiers, L. Willemot, Laura McDonald, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4823-4823
Open Access | Times Cited: 6
Anne Rogiers, L. Willemot, Laura McDonald, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4823-4823
Open Access | Times Cited: 6
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study
Nathalie Vanlaer, Iris Dirven, Bart Neyns, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1638-1638
Open Access | Times Cited: 1
Nathalie Vanlaer, Iris Dirven, Bart Neyns, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1638-1638
Open Access | Times Cited: 1
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study
Danielle B. Tometich, Carley Geiss, Melinda Leigh Maconi, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 6
Closed Access | Times Cited: 1
Danielle B. Tometich, Carley Geiss, Melinda Leigh Maconi, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 6
Closed Access | Times Cited: 1
Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples
Filippo Ugolini, Luca Tinunin, Filippo Nozzoli, et al.
Applied immunohistochemistry & molecular morphology (2024) Vol. 32, Iss. 8, pp. 389-394
Open Access | Times Cited: 1
Filippo Ugolini, Luca Tinunin, Filippo Nozzoli, et al.
Applied immunohistochemistry & molecular morphology (2024) Vol. 32, Iss. 8, pp. 389-394
Open Access | Times Cited: 1
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Katharina C. Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access
Katharina C. Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access
Assessment of Quality of Life in Patients with Advanced Melanoma Receiving Immunotherapy with Checkpoint Inhibitors
A. S. Sarmatova, R. V. Orlova, Natalia V. Zhukova, et al.
Effective Pharmacotherapy (2023) Vol. 19, Iss. 16, pp. 42-47
Open Access
A. S. Sarmatova, R. V. Orlova, Natalia V. Zhukova, et al.
Effective Pharmacotherapy (2023) Vol. 19, Iss. 16, pp. 42-47
Open Access
